Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).
Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Pastina P, et al. Among authors: ricci v. Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100279 Free PMC article.
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.
Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P. Pastina P, et al. Among authors: ricci v. J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68. J Thorac Dis. 2017. PMID: 29221287 Free PMC article.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Correale P, et al. Among authors: ricci v. Cancer Biol Ther. 2010 May 1;9(9):685-93. doi: 10.4161/cbt.9.9.11441. Cancer Biol Ther. 2010. PMID: 20697196 Clinical Trial.
Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.
Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P. Cusi MG, et al. Among authors: ricci v. Cancer Immunol Immunother. 2015 Sep;64(9):1159-73. doi: 10.1007/s00262-015-1711-7. Epub 2015 Jun 2. Cancer Immunol Immunother. 2015. PMID: 26031574 Free PMC article. Clinical Trial.
469 results